Skip to main content

Market Overview

Hoth Therapeutics Plans To Test HT-003 API In Inflammatory Bowel Disorders; Shares Spike

  • Hoth Therapeutics Inc (NASDAQ: HOTHplans to expand the development of the HT-003 active pharmaceutical ingredient (API) to pursue a new indication for the treatment of inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis. The company has executed an option agreement with Isoprene Pharmaceuticals to investigate the potential.
  • In preclinical studies, the API of HT-003 has shown encouraging anti-inflammatory action and targets the retinoic acid metabolism pathway.
  • HT-003 can potentially inhibit the TLR2 signaling pathway, thus suggesting the effectiveness of this drug candidate not only for acne but in a broad range of diseases driven by overactive inflammatory responses to bacteria.
  • Hoth plans to investigate the therapeutic potential of the HT-003 API using relevant ex vivo tissue models and other in vitro molecular studies. This work will complement Hoth's current research activities investigating the therapeutic potential of HT-003 for the treatment of acne and psoriasis.
  • Price Action: HOTH gains 3.3% at $3.13 in premarket trading on last check Thursday.

Related Articles (HOTH)

View Comments and Join the Discussion!

Posted-In: Irritable Bowel SyndromeBiotech News Penny Stocks FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at